XML 16 R4.htm IDEA: XBRL DOCUMENT v3.24.2.u1
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Operating Expenses:        
Research and development $ 2,601 $ 3,162 $ 5,842 $ 6,341
General and administrative 2,922 3,713 6,282 7,378
Total operating expenses 5,523 6,875 12,124 13,719
Operating loss (5,523) (6,875) (12,124) (13,719)
Other income (expense):        
Investment income, net 493 668 1,082 1,338
Other expense, net (14) (150) (201) (163)
Total other income 479 518 881 1,175
Net loss before benefit from income taxes and noncontrolling interests (5,044) (6,357) (11,243) (12,544)
Benefit from income taxes 0 (2,330) (798) (2,330)
Net loss (5,044) (4,027) (10,445) (10,214)
Less - net income (loss) attributable to noncontrolling interests 0 0 0 0
Net loss attributable to Lisata Therapeutics, Inc. common stockholders $ (5,044) $ (4,027) $ (10,445) $ (10,214)
Basic and diluted loss per share        
Lisata Therapeutics, Inc. common stockholders- basic (in usd per share) $ (0.61) $ (0.50) $ (1.26) $ (1.28)
Lisata Therapeutics, Inc. common stockholders - diluted (in usd per share) $ (0.61) $ (0.50) $ (1.26) $ (1.28)
Weighted average common shares outstanding        
Basic shares (in shares) 8,308 8,021 8,301 8,004
Diluted shares (in shares) 8,308 8,021 8,301 8,004